Clinical Significance of ABC Transporter Expression in Patients with Hepatocellular Carcinoma

Abstract

To gain insight into the clinical significance of expression of ABC transporter antigen in patients with hepatocellular carcinoma (HCC), we used immunohistochemistry to determine the patterns of ABCB1, ABCC1 and ABCG2 expression in 30 resected HCC tissues, 26 paired adjacent nonneoplastic tissues and 9 cirrhosis tissues accompanied with chronic hepatitis B virus infection in this study. It was found that the expression rates of ABCB1, ABCC1 and ABCG2 were 56.7 %, 93.3 % and 83.3 % in patients with HCC, respectively. ABCB1 and ABCC1 were expressed significantly differently among HCC, adjacent non-neoplastic and cirrhosis tissues. There were no significant differences in the clinical factors associated with the expression of these three ABC transporter antigens. Furthermore, preoperative TACE treatment didn't affect the expression of these three ABC transporters. Moreover, patients with higher expression of both ABCC1 and ABCB1 showed significantly shorter disease-free survival (DFS) than those with lower expression of both antigens (P<0.01).Therefore, higher expression of ABCC1 and ABCB1 might be an unfavorable prognostic factor in patients of HCC, and represent an important hurdle to chemotherapy.

CFTR reduces the proliferation of lung adenocarcinoma and is a strong predictor of survival in both smokers and non-smokers

“…Drug efflux catalyzed by the multidrug resistance transporters MDR1 and MRP1 constitutes an essential mechanism of cancer chemoresistance. Previous research revealed associations of ABCB1 transcript levels with poor outcomes in ovarian cancer (Johnatty et al 2013 ; Sun et al 2016 ), gastric cancer (Oliveira et al 2014 ) and HCC (Fan et al 2016 ), whereas inverse trends have been reported for HNSCC (Warta et al 2014 ) and ccRCC (Reustle et al 2018 ). In agreement with these findings, we observed protective effects of ABCB1 expression on survival in ccRCC (logrank P = 1.4*10 –6 , HR 0.49, CI 0.36–0.66) and HNSCC (logrank P = 9.6*10 –5 , HR 0.59, CI 0.43–0.74; Table 1 ).…”

Persistent Homology Identifies Pathways Associated with Hepatocellular Carcinoma from Peripheral Blood Samples

“…Interestingly, several pathways identified by our PH method have been previously associated with HCC, or their association has been suggested by other computational approaches. For completeness, we provide a list: genetic information processing pathways (RNA polymerase [42], protein processing in endoplasmic reticulum [43], and base excision repair [44,45]), environmental information processing pathways (ABC transporters [46][47][48] and apelin signaling pathway [49,50]), a cellular processes pathway (p53 signaling pathway [51][52][53][54]), organismal systems pathways (IL-17 signaling pathway [55,56] and synaptic vesicle cycle [57]), and several metabolism pathways (riboflavin metabolism [58], citrate/TCA cycle [59][60][61], ascorbate and aldarate metabolism [62,63], drug metabolismcytochrome P450 [48,[64][65][66][67], glycine, serine, and threonine metabolism [48,64,68], primary bile acid biosynthesis [64], histidine metabolism [64], beta-alanine metabolism [64], tryptophan metabolism [54,64,69,70], pantothenate and CoA biosynthesis [58,[71][72][73], ...…”